DNA12 TRX319 CAR-T MS - Clinical Trial
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
DNA12: A Phase 1/2a, Open-Label, Dose-Escalation Study to Evaluate
the Safety and Preliminary Efficacy of TRX319 in Subjects
with Primary or Secondary Progressive Multiple Sclerosis
Principal Investigator
Suma Shah, MD
Neurologist
Protocol Number
IRB:
PRO00119500
NCT:
NCT07477639
Phase
Phase I/II
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment